Key result
ECG abnormalities in systemic autoimmune diseases indicate underlying cardiac involvement prompting advanced imaging and intervention.
Case Report (n=2)
Answers are grounded in this paper and cite their sources.
ECG abnormalities in patients with systemic autoimmune diseases should prompt advanced cardiac imaging to detect early cardiac involvement and guide appropriate immunosuppressive and cardiac therapies.
CASE 1 Clinical presentation A 28-year-old woman with a history of active systemic lupus erythematosus (SLE) was admitted due to persistent shortness of breath and pleuritic chest pain for 2 weeks. Vital signs included a temperature of 37.6°C, blood pressure of 103/54 mmHg, heart rate of 88 beats/minute, respiratory rate of 18 breaths/minute and oxygen saturation of 100% on room air. The physical examination revealed dual heart sounds, no pericardial rub, clear lung auscultation, and vasculitic rashes over the fingertips. What are her electrocardiogram (ECG) findings at presentation [Figure 1]?Figure 1: Case 1: ECG at presentation.ECG interpretation The ECG showed normal sinus rhythm with characteristic diffuse, 1-mm concave ST-segment elevation, concomitant PR depression in I, II aVF and V5–V6, and reciprocal ST depression and PR elevation in aVR, which are changes suggestive of pericarditis. Atrial or ventricular arrhythmias, sometimes seen in concomitant myocarditis, were not evident in this ECG. Laboratory tests confirmed active SLE, with anaemia, hypocomplementaemia, as well as and elevated erythrocyte sedimentation rate and anti-dsDNA titres. Transthoracic echocardiography (TTE) demonstrated small pericardial effusion, global hypokinesia and impaired left ventricular systolic function with a left ventricular ejection fraction (LVEF) of 45%. Cardiac magnetic resonance (CMR) imaging was consistent with myopericarditis and possible effusive–constrictive pericarditis. Clinical course The patient received 3 days of intravenous (IV) methylprednisolone (500 mg/day), followed by a steroid taper, IV cyclophosphamide and daily colchicine (0.5 mg). The treatment improved her symptoms and laboratory markers of disease activity. The patient was discharged after 2 weeks. At her 3-month follow-up, exertional dyspnoea and vasculitic rashes had resolved. Furthermore, TTE demonstrated resolution of pericardial effusion as well as an improved LVEF of 55%. CASE 2 Clinical presentation A 34-year-old woman was referred for dizziness and palpitations with episodes of unprovoked presyncope. She had no significant family history. On examination, her blood pressure was 165/78 mmHg, heart rate was 51 beats/minute, respiratory rate was 18 breaths/minute and oxygen saturation was 98% on room air. Physical examination revealed dual heart sounds that were slow and irregular. Chest radiograph was normal. Investigations revealed mildly elevated serial troponin at 52 ng/L. She had normal thyroid and renal function. Her electrolytes were not deranged. What are her ECG findings at presentation [Figure 2]?Figure 2: Case 2: ECG at presentation.ECG interpretation The ECG revealed a ventricular rate of 49 beats/minute (ventricular R–R interval of 1216 ms) and an atrial rate of 91 beats/minute (atrial R–R interval of 654 ms). There was complete atrioventricular dissociation. A broad QRS duration (>120 ms) and a dominant S wave (rS complex) were seen in V1, and a corresponding broad (>120 ms), monophasic R wave with an ‘M’-shaped QRS complex was present in leads I, aVL and V6. These findings were suggestive of a left bundle branch block (LBBB). In addition, there was a dominant R wave in lead I and a dominant S wave in leads III and aVF. The findings revealed complete heart block, LBBB and left axis deviation. Clinical course A coronary angiogram demonstrated normal coronaries. The CMR imaging demonstrated extensive mid-myocardial and near-transmural late gadolinium enhancement (LGE), mainly in the basal anterior left ventricular wall and basal septum, as well as subendocardial LGE in the mid-cavity anterolateral wall and anterolateral papillary muscle. The patient underwent positron emission tomography and computed tomography (PET-CT), which demonstrated heterogeneous increased F-18 fluorodeoxyglucose (FDG) avidity along the septal wall and basal segment of the left ventricle, suspicious of underlying cardiac sarcoidosis in the given clinical context. The finding of an FDG-avid splenic lesion was suspicious of extracardiac involvement. An endomyocardial biopsy performed from the right ventricle revealed mild interstitial oedema, but no discernible fibrosis or increased glycogen or amyloid deposits; there were no inflammatory infiltrates or granulomas. Nevertheless, this was likely due to a false-negative biopsy result, and the patient was diagnosed with probable cardiac sarcoidosis. A dual-chamber automated implantable cardioverter defibrillator was implanted. The rheumatologist prescribed immunosuppression with tapering doses of methotrexate and prednisolone, with interval resolution of the abnormalities seen on PET-CT. DISCUSSION Rhythm and conduction disorders are important manifestations of cardiac involvement in systemic autoimmune disease, as summarised in Table 1. Cardiovascular involvement in patients with autoimmune disease is usually insidious or has no typical clinical features until the disease is severe and irreversible, even life-threatening.[1,2] The underlying pathophysiological mechanism of cardiac manifestations in autoimmune disease is multifaceted. It has been described as, but not limited to, a direct autoimmunity-related infiltration and destruction of the conduction system (SLE,[1] rheumatoid arthritis [RA][1]), a sequela of myocarditis resulting in heart failure, cardiomyopathy or arrhythmia (SLE[1]), patchy myocardial fibrosis involving the cardiac conduction system (systemic sclerosis [SSc][1,3]), myocardial fibrosis or granulomatous scar as a substrate for atrial and ventricular tachyarrhythmia (in SSc[3] and sarcoidosis,[4] respectively), and microvascular disease that leads to vasospasm resulting in myocardial infarction of unaltered coronary arteries in SSc.[5] Therefore, it is imperative to remain vigilant to ensure appropriate investigations are carried out to facilitate early diagnosis and intervention.Table 1: Summary of rhythm disorders, conduction disorders and cardiac manifestation in systemic autoimmune disease.[ 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]The ECG is widely used as a screening tool for cardiovascular health. However, it lacks specificity in detecting early or preclinical myocardial lesions. While some studies have reported an independent association between autoimmune disease activity and ECG changes,[8] others have suggested that ECG abnormalities were too variably defined to have a clear conclusion about their usefulness as predictors of subsequent events.[9] Nonetheless, the two cases presented here illustrate cardiac involvement in autoimmune diseases with typical ECG abnormalities, prompting further cardiac imaging to guide treatment. A multidisciplinary team consisting of rheumatologists, cardiologists and other specialists is necessary to provide clinically orientated care tailored to the individual. There are four main principles in the general management of cardiac involvement in systemic autoimmune diseases. First, early diagnosis and disease monitoring with regular syndromic surveillance of cardiovascular health is vital in patients with systemic autoimmune diseases. Although the ECG can be used as a screening tool, it should also be performed promptly if there is suspicion of cardiac involvement. Advanced imaging techniques such as TTE, CMR, PET-CT and, in some instances, endomyocardial biopsy, may be considered to detect subclinical cardiac involvement.[15] Second, reducing systemic inflammation and disease activity in the heart is imperative. The underlying systemic autoimmune diseases should be treated with immunosuppressive and immunomodulatory therapies, aiming for remission status. Specific treatment regimens depend on the type of systemic autoimmune disease, and these include corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, and biological agents such as tumour necrosis factor inhibitors and B-cell depletion therapies. Third, to prevent cardiovascular diseases, it is vital to optimise the management of cardiovascular, risk factors, including smoking, hypertension, diabetes mellitus and dyslipidaemia. Lastly, the treatment of cardiac disease should align with the current evidence-based practice guidelines for cardiovascular diseases. For instance, renin–angiotensin–aldosterone system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and sodium–glucose co-transporter-2 inhibitors are used to manage heart failure with reduced ejection fraction.[16] In conclusion, cardiac involvement in systemic autoimmune diseases is a complex interplay of immune-mediated processes significantly affecting patient outcomes. Alterations in ECG should prompt advanced cardiac imaging modalities to facilitate the early detection of cardiac involvement in the preclinical stage of the disease, allowing for early intervention with prognostic implications. Financial support and sponsorship Nil. Conflicts of interest Poh KK and Sia CH are members of the SMJ Editorial Board and were thus not involved in the peer review and publication decisions of this article. SMC CATEGORY 3B CME PROGRAMME Online Quiz: https://www.sma.org.sg/cme-programme Deadline for submission: 6 pm, 06 August 2024
No takes yet. Share an insight, caveat, or question.
Tan et al. (2024) conducted a case report in Cardiac disorders in rheumatological conditions (n=2). Systemic autoimmune diseases was evaluated. Electrocardiographic abnormalities in patients with systemic autoimmune diseases can indicate underlying cardiac involvement, prompting advanced imaging and early intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: